iPSC models have the potential to be instrumental in advancing our understanding of AD pathophysiology and in identifying novel drug treatments. By testing compounds on these cellular models, researchers can screen for potential therapeutics more efficiently, potentially accelerating the development of effective treatments for AD.
By generating human neurons from both Alzheimer's disease (AD) patient-derived iPSCs and normal iPSCs engineered to carry risk-associated AD genetic mutations, Creative Bioarray's iPSC-derived models are invaluable tools for investigating the mechanisms underlying AD progression.
Online Inquiry
